biotech · Relapsed/Refractory Multiple Myeloma · Relapsed/Refractory Autoimmune Diseases
Nanjing Legend Biotech
Nanjing Legend Biotech Co.
Legend Biotech is a biotech organization headquartered in Somerset, USA. Primary therapeutic focus areas include Relapsed/Refractory Multiple Myeloma, Relapsed/Refractory Autoimmune Diseases, Multiple Myeloma, Gastric Ca
2101 Cottontail Lane, Somerset, New Jersey 08873, US HQ
2,457 Employees
NMPA registrant Type
Company details
- Status
- Public
- HQ
- 2101 Cottontail Lane, Somerset, New Jersey 08873, US
- Employees
- 2,457
- Programs
- 36
- Drugs
- 17
- Patents
- 26
CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product
Phase 1 · mab · Relapsed/Refractory B-cell Malignancies
CD19/CD20 Dual-Target in vivo CAR-T Lentiviral product for Relapsed/Refractory B-cell Malignancies is a Phase 1 program (mab) at Nanjing Legend Biotech Co. with 1 ClinicalTrials.gov record(s).
Internal code LB2409-0001
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Nanjing Legend Biotech Co.
- Phase
- Phase 1
- Modality
- mab
- Indication
- Relapsed/Refractory B-cell Malignancies
- Status
- active
- Trials
- 1